In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations

Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)-piperazin-2-one), is a new dipeptidyl peptidase IV inhibitor used for the treatment of type II diabetes mellitus. The in vitro metabolic pathways of evogliptin were identified in human hepatocytes, liver microsom...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Hyeon-Uk, Kim, Ju-Hyun, Lee, Dae Young, Shim, Hyun Joo, Lee, Hye Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332232/
https://www.ncbi.nlm.nih.gov/pubmed/26690104
http://dx.doi.org/10.3390/molecules201219808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332232/
https://www.ncbi.nlm.nih.gov/pubmed/26690104
http://dx.doi.org/10.3390/molecules201219808

Ejemplares similares